Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Vaccination

Adjuvanted flu vaccine for over-65s effective in more than 60% of cases this winter, says PHE

While the overall success rate of the vaccine programme against all flu strains for all age groups during the 2018–2019 flu season was 44.3%, this rose to 62.0% in people aged over 65 years who received the new adjuvanted flu vaccine.

Flu vaccine being administered

Source: Shutterstock.com

The success rate of the new adjuvanted flu vaccine, which is designed to be effective against three flu strains, was 62% in people aged over 65 years

The new adjuvanted flu vaccine given to people aged over 65 years in England for the first time in winter 2018 had a success rate of more than 60% in protecting them against the virus, according to statistics from Public Health England (PHE).

The overall success rate of the vaccine programme against all flu strains for all age groups during the 2018–2019 flu season was 44.3%, according to the annual flu report, which was published on 30 May 2019. In the previous flu season, the overall figure was 15.0%.

The effect of the Live Attenuated Influenza Vaccine given to children and young people aged 2–17 years was 48.6% in the 2018–2019 season.

In the 18–64 years age group, flu vaccination, for all vaccines, was effective in 44.2% of cases; the success rate, for all vaccines, in those aged over 65 years was 49.9%.

However, the success rate shot up to 62.0% in people aged over 65 years who were only given the new adjuvanted flu vaccine, which is designed to be effective against three flu strains.

Uptake of flu vaccinations fell this season for those aged over 65 years, compared with the 2017/2018 season (72.0%, down from 72.9%), people aged under 65 years but over six months with one or more underlying clinical risk factor (48.0%, down from 49.7%), and pregnant women (45.2%, down from 47.0%).

PHE also reported that influenza A(H1N1)pdm09 was the main strain of the virus circulating in the 2018/2019 season, although influenza A(H3N2) also circulated later on in the winter.

The PHE report said ‘low-to-moderate’ levels of flu activity were seen in the community, although the impact on secondary care in terms of hospitalisations and admissions to intensive care units was ‘high’.

Commenting on the figures, Richard Pebody, head of flu surveillance at PHE, said: “We’re pleased that the adjuvanted vaccine, which was offered to older adults for the first time this year in England, provided encouraging protection against the main circulating strains this winter.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206618

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £81.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.